Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chimeric antigen receptor T cell therapies - Strand Therapeutics

Drug Profile

Research programme: chimeric antigen receptor T cell therapies - Strand Therapeutics

Alternative Names: CAR T Cell therapy - Strand Therapeutics; CAR-T CD19 cell therapy - Strand Therapeutics; mRNA-based CAR-T immunotherapy - Strand Therapeutics

Latest Information Update: 19 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Strand Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Nov 2021 Chimeric antigen receptor T cell therapies - Strand Therapeutics is available for licensing as of 30 Nov 2021. https://www.strandtx.com/strand-partnership
  • 09 Nov 2021 Strand Therapeutics receives phase I SBIR grant from National Cancer Institute for CAR T cell therapies in Non-Hodgkin’s lymphoma
  • 09 Nov 2021 Strand Therapeutics has patent protection for drug delivery system for chimeric antigen receptor T cell therapies as of November 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top